Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Burn-Rate is down Revenue is up and they have enough cash to drive this Goldmine deep into profitability .
Stock was overbought so this pullback is no surprise .
Everything is on track ...Good Buy here
it will be on the Market earlier than 2016 if Par Pharma wins the battle ...
Such Patent lawsuit is a very normal process in the generic area . Par Pharma is a giant they know what they do ,they would not bring the generic version of the suboxone film to Market if they know that IGXT patent is weak so everything is still on track here .
IGXT-DD -- Lifetime Opportunity here
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow in the next 6 months .
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.
IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $30 M
Cash: $3 M
Price:0.60
Burn-Rate : $1.5 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
I got it from the CEO itself per mail .. I would never post something which is not true
Maybe you forget the new upcoming Partnerships ..
Load up NOW before she breakouts ...
IGXT & TBUFF best OTC Biotech Plays
Time to load up the brutally underpriced cheapis here
Put High GTC Sell Order In Like $5 Guys ...
Q.: What can you do to prevent your shares holdings from being shorted?
A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.
There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes. And don't forget to move your limit order up when the price starts to recover, then, that way your shares can't be shorted - not much but helps :D.
Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.
In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
Another run to $3++ imminent .. Buy the cheapis before she explodes again..
Only 10 M shares on the float
We have a New Big Investor in IPCI ..
http://www.theflyonthewall.com/permalinks/entry.php/IPCIid1867308/IPCI-Sabby-reports--passive-stake-in-Intellipharmaceutics-
15:33 EDT IPCI Sabby reports 5.92% passive stake in Intellipharmaceutics
Back in this Goldmine
FIRST FDA APPROVAL EXPECTED IN THIS 3Q 2013....
This LOW FLOAT Monster awaiting 8 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including two Potential Blockbuster .CEO is the largest Shareholder with over 6 Million Shares .
FOCALIN alone which is Partnered with Par Pharma will drive this Sleeping Giant into Profitability quickly after Market Launch because of the low Burn-rate of around $7 M a year !
4-6 FDA APPROVALS COMING WITHIN NEXT 12 MONTHS = NEXT BILLION DOLLAR COMPANY HERE !
Patience here will payoff big time ! GLTA
Intellipharmaceutics (IPCI)
Market Cap:$ 38 M
Price: $1.90
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercia/launch of the product by Par .
We will hear something in the coming days if Reckitt Benckiser tried to fight for their patents, but if we hear nothing before ANDA acceptance by FDA then this would be very good news for IGXT .
------
Incentives and Protections
•180-day market exclusivity
–First applicant to submit a substantially complete ANDA(first-to-file)
–May be shared by multiple applicants
–Subject to forfeiture
•30-month stay of FDA approval
–If patent owner or NDA holder sues the ANDA applicant
for patent infringement within 45 days of receiving notice
of the Paragraph IV certification
–Runs from date of notification or expiration of NCE
exclusivity
–May be lengthened or shortened by the court
Paragraph IV Deadlines
•
Notification letter:20 days
Upon ANDA acceptance for filing, the applicant must notify
the NDA holder and patent owner of the ANDA within 20
days. The notice must include a detailed statement of the
factual and legal basis of the opinion of the applicant that the
patent is invalid or will not be infringed.
•
Lawsuit:45 days
Upon notification, the NDA holder and patent owners have 45
days in which to initiate an action for patent infringement. If
such an action is brought within 45 days, the ANDA is subject
to a 30-month stay of FDA approval beginning on the date the
notification letter was received
TBUFF & IGXT are stocks which is a MUST HAVE at this ridiculous price .
I send Zerbe an email regarding the S-1 filing will post his response here .
Big Jump to $1++ is coming very soon
The market cap of $21 Million is still ridiculous but this will change soon once more investors discover this pure Goldmine .
Great News out today and more to come ..
Another 1 NDA and 1 ANDA filing coming before year + New Partnerships ...The Big News starts to come in and this Goldmine still trading at a ridiculous Market cap of $33 million what monster bargain . Again its a lifetime opportunity for those who have the patience .
Another fantastic pick is TBUFF check it out guys ..
Next Earnings will be great again i think they will reach profitability by year end or early next year . This Low Float Monster is a sleeping giant which will awake in the coming weeks .
TGT $2-4 within next 12 months .GLTA
http://www.allotcbb.com/quote.php?symbol=tbuff
First Quarter 2013 Highlights:
Revenues increased 18% to $3.4MM in Q1-2013 vs. Q1-2012
Gross profit up 36% in Q1-2103 vs. Q1-2012
Tribute's sales force launched Cambia(R) throughout Canada in Q1-2013 to include primary care physicians
The Company completed a private placement of units of its securities in Q1-2013 for aggregate gross proceeds of approximately US $4.6MM
"We are executing our plan and are now in full launch mode with Cambia®" said Rob Harris, CEO of Tribute. "We believe Cambia® has the potential to gain a significant proportion of the $150 million Canadian migraine market. We believe it is the only available prescription non-steroidal anti-inflammatory drug ("NSAID") available with an indication for the acute treatment of migraine attacks with or without aura in adults in Canada." Mr. Harris went on to state, "We are pleased with our results for Q1-2013. Our promoted products including Bezalip SR and Soriatane continue to show good growth in Canada. We are pleased with our business development efforts and feel confident in our ability to bring new products to Canada. Furthermore, we are making good progress on the preparation of the Bezalip SR IND in the US and are still on track to file this with the FDA before the end of the year."
MEGA Product Pipeline (all product on the Market except Bezalip in USA and MycoVA which is currently pending regulatory approval in Canada) :
Product Indication Geographic Right Market Size
Bezalip® SR Mixed dyslipidemia US & Canada $20 B
NeoVisc® Osteoarthritis of the knee Global $1.4 B
Soriatane® Moderate to severe psoriasis Canada $210 M
Uracyst® Interstitial cystitis Global $151 M
CAMBIA® Acute migraine headaches Canada $150 M
Collatamp G® Prevention of post-operative infection Canada $20 M
Gelfoam® Hemostatic device Canada $30 M
MycoVa™ Nail fungus Canada $30 M
Canadian Business Includes 7 Marketed Products Including Recently Launched CAMBIA
Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in
the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam® in Canada
.MycoVa is currently is pending regulatory approval in Canada.
TBUFF-DD.. A MEGA Lifetime Opportunity here
This Undiscovered and Low Float Goldmine is BRUTALLY Underpriced . They have already 7 Drugs on the Market and 1 Potential Blockbuster(Bezalip SR®) close to enter the US Market .
The Annual Revenue hits $13 Mil in last year almost similar to Antares Pharma (ATRS) which has a Market Cap of $570 M .
This Stock should trade over $5 per Share instead of $0.40 . This is your Opp to get in very very Cheap .GLTA
Ticker: TBUFF
Market Cap: $19.7M
Shares Out: 51.0M
Fully Diluted Shares: 68.5M
Insider Ownership: 56.7%
BRUTAL Insider Buying
http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions
Presentation May 2013
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b220d091c62d6123d81e.pdf
Fact Sheet--MUST READ
http://content.stockpr.com/tributepharma/media/cceaf7664429c13e4f2159e8abf81c60.pdf
Specialty Pharma with High Growth,Low Risk Business Model
Tribute primarily licenses products that have already
progressed through significant R&D investment and
in many cases,already received regulatory approval
in Canada or other countries. To date,Tributehas
developed or in -licensed 8 products,7 of which
the Company is currently selling.The Company does not invest heavily in R&D, but rather looks tobenefit after the
R&D risk is mitigated.
Growing Revenues
The Company, formerly known as Stellar Pharmaceuticals,
completed its acquisition of privately held Tribute Pharmaceuticals in December of 2011 and changed its name to Tribute in January 2013. Gross revenues havegrown to $13.1
million for the 12 months ended September 30, 2012 when including
revenues of both companies for the last four quarters. In October of 2012 Tribute launched a key new product, CAMBIA®, for the treatment of migraine headaches, which addresses a $150 million market in Canada and is expected to make a meaningful contribution to revenues in Q4 and beyond.The Company is actively looking to build out its product portfolio to generate additional near term revenues.
Established Sales Infrastructure in Canadian Market
Canada is the 10th largest healthcare market in the
world, driven by its national healthcare plan which covers 100% of its population. It’s a geographic market served by very few specialty pharmaceutical companies.With 24 full time sales people,
Tribute sells and distributes to doctors,hospitals and clinics through out Canada. Leveraging its sales and distribution infrastructure,Tribute negotiates for the exclusive license to sell products developed by companies like Pfizer in the Canadian market.
Significant Potential of Bezalip SR® in U.S.Market
Tribute has licensed the exclusive rights to Bezalip SR,
a drug that lowers cholesterol and triglycerides, in the U.S. and Canada.Tribute now sells Bezalip SR in Canada and is developing
its strategy to obtain FDA approval in the U.S.
, addressing the $3 billion U.S.fibrate market, a subset of
the $20 billion U.S. and Canadian dyslipidemia market
.Tribute recognizes Bezalip SR in the U.S as a significant asset and seeks to maximize this opportunity.Bezalip SR is approved in more than 40 countries worldwide.
Accomplished Management Team
Tribute’s management team and board members have
successfully built pharmaceutical companies that have been subsequently sold for valuations over $3 billion. Their industry relationships, expertise in licensing
and building sales forces are key value drivers for the Company.
Patent expiration for Tadalafil is early 2016 and if you look at the revenue projection above it shows sales for 2017 .
Please guys do some dd before posting .Thanks
6 million warrants oustanding most of them (4 Mil priced at .59 ) means .
I think almost 85% of warrants exercised during last 6 months means there is a huge chance to break trough $1 in the coming days if the volume is like last week .
Put high GTC sell order in like $5 for your shares ...
Q.: What can you do to prevent your shares holdings from being shorted?
A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.
There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes. And don't forget to move your limit order up when the price starts to recover, then, that way your shares can't be shorted - not much but helps :D.
Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.
In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
realistic number are $2-3 before FDA decision, dont forget the upcoming new Partnerships and more NDA/ANDA submissions before year end .
This is a no brainer here at this ridiculous price .
Fourth highest Volume yesterday in Canada since listing . Looks like we are very close to some big news like new Partnership or the ANDA filing of Par drug .
Gary please do some update on the frontpage here ..
update the aegis article and the fundamentals
0.63 in canada ..Mega Breakout is coming
Only 57 M Fully diluted NOT 69 M see latest presentation .
Our big payday is coming soon ..
the mod function expire if you stop or post rarely on the board .
They running out of cash before year end means they need to raise more cash in the coming weeks .
The other point is that their lupus drug is not effective like the competitors . I think the Phase 3 results will be a disaster which will be the end of this Company .
We will see $2 and lower after dilution ..Markt my words
just monthly option expiration
it was a good day to take profit .This will pullback to $4 and lower in the coming days .
Oh please stop the spamming .. Do you have no friends take a pause buddy and go to bars or elsewhere .terrible
On Last FDA decision it moved over $1++ and the pipeline at that time was in early stage .
Now almost all procducts are in late stage and some of them close to NDA and ANDA filing before year end .
This time is different than last time. So please basher dont waste your time here and move on bye bye .
Now get ready for the new Partnerships which Zerbe mentioned in his las mail .
For those who wants very cheap shares should buy more today before all the speculators jumping in .
Im sure that we will see $1++ in the coming weeks .
I hate lies and misleading ,everyone who read the pure garbage of this gary would run away and never invest in this stock .
Again if you dont like the stock then sell and go away . the garbage you posting here is hurting the stock .
IGXT was a fantastic trading stock earlier before you amateurs have started to spamming here .
Please sell and go away and this stock would do very well .
I was many times in and out in this stock and make big money especially on the FDA runup in 2011 it was one of my best plays in 2011 .
Im now back in again for the upcoming FDA runup . If you know how to play this gem then you can make big money .
This is a different time than it was 3 years ago means now all products are close to enter the Market .
The long awaited run could start this year if there is no stockmarket crash .
Here is it in english
Good day, Mr. xxxxxxx,
first I agree with you that the share has enormous potential for growth exists. As far as the purchase of shares, I have already done so. Not only did I not only sold my shares since the company's founding, I have in addition, around half a million shares bought and not by exercise of options sold again. This is also according to have been published.
What the NDA-acceptance, the letter from the FDA is simply not yet, even though he is long overdue for weeks. We know from a reliable source that the NDA is accepted but can not risk a Presseveroeffentlichung, without the document to have in their hands.
A problem is certainly the market in which our share is traded. Our impression is that its range of high speculative OTC-investors the environment in which we operate, does not understand and is waiting on a unrealistic rapid Return. Par is a good example. We have a very successful cooperation with par, one of the leading generics company in the United States. Since the success of a generic development industry much of which founding members, ongoing Entwiklungsprojekt secret before the competition, we have a strict confidentiality agreement compared to our partner and not publish details of the project. This leads to the various message boards constantly to unfounded opinions expressed, the doubts about the project and the project's progress and the Sharepreis negative influence. I could give you a number of other examples how you should, where speculation by uninformed and unfounded assertions heruntergeredet is the price for no reason. I believe that its broader basis of "sophisticated" investors could stop this trend.
We have a lot of thought about it, we can improve the share price, and I am always grateful for constructive suggestions and open-minded. I also believe, however, that with our Hauptentwicklungsprojekten now so we have made good progress, that the price should reflect this development in the foreseeable future.
With kind regards,
H.Zerbe
Good News coming guys ... CEO say NDA is accepted here is his original mail . I ask him many questions .
Can someone translate this please
Guten Tag, Herr xxxxxxx,
Erstmal stimme ich mit Ihnen ueberein, dass die Aktie enormes Steigerungspotential hat. Was den Kauf von Aktien anlangt, das habe ich bereits getan. Nicht nur habe ich keine einzige meiner Aktien seit Gruendung des Unternehmens verkauft, ich habe darueber hinaus ca. eine halbe Million Aktien durch Ausuebung von Optionen gekauft und nicht wieder verkauft. Das ist auch entsprechend publiziert worden.
Was die NDA-Akzeptanz anlangt, der Brief von der FDA liegt einfach noch nicht vor, obgleich er seit Wochen ueberfaellig ist. Wir wissen aus sicherer Quelle, dass die NDA akzeptiert ist aber koennen eine Presseveroeffentlichung nicht riskieren, ohne das Dokument in Haenden zu haben.
Ein Problem ist sicherlich der Markt, auf dem unsere Aktie gehandelt wird. Unser Eindruck ist, das seine Reihe von hoch spekulativen OTC-Investoren das Umfeld, in dem wir operieren, nicht versteht und auf einen unrealistisch schnellen Return wartet. Par ist ein gutes Beispiel. Wir haben eine ausserordentlich erfolgreiche Kooperation mit Par, einem der fuehrenden Generikaunternehmen in den USA. Da der Erfolg einer Generikaentwicklung wesentlich davon abhaengt, laufende Entwiklungsprojekt vor der Konkurrenz geheimzuhalten, haben wir eine strikte Geheimhaltungsverpflichtung gegenueber unserem Partner und publizieren keine Einzelheiten des Projektes. Das fuehrt auf den verschiedenen Messageboards staendig zu unfundierten Meinungsaeusserungen, die das Projekt und den Projektfortschritt anzweifeln und den Sharepreis negativ beeinflussen. Ich koennte Ihnen eine Reihe anderer Beispiele anfuehren, wo durch uninformierte und unfundierte Spekulationen der Preis grundlos heruntergeredet wird. Ich glaube, dass seine breitere Basis von “sophisticated” Investoren diesen Trend aufhalten koennte.
Wir machen uns sehr viele Gedanken darueber, wir wir den Aktienkurs verbessern koennen, und ich bin fuer konstruktive Vorschlaege immer dankbar und aufgeschlossen. Ich glaube aber auch, dass wir mit unseren Hauptentwicklungsprojekten mittlerweile so gute Fortschritte gemacht haben, dass der Preis in absehbarer Zeit diese Entwicklung reflektieren sollte.
Mit freundlichen Gruessen,
H. Zerbe
100k shares thats less than 0.5% of all shares outstanding That's not worth mentioning.
---
Product Application Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- Submit NDA in March 2013
INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study